Innovation Pharmaceuticals Inc (IPIX)

[petemantx]

I am hoping that when Brilacidin becomes known as an excellent complementary drug for vaccines and proves its broad spectrum of uses that this will down the road propel IPIX's other drug, Kevetrin, into a broad, broad swath of trials as a an adjunct to many other cancer treatment drugs.

Many BPs will be shaking their heads and wondering how they ever let IPIX get away with two drugs possessing such explosive potential in so many high revenue streams of medicine.

Next week sometime starts the final step to allowing Brilacidin to be put to work on human patients for CV - hope it is for both a treatment and as a vaccine adjunct.